Moderna Earnings: What to Look For From MRNA
Wed, February 23, 2022, 5:53 AM·4 min read
In this article:
MRNA
-5.28%
Significant Event | 1d
Moderna Says Initiates Phase 3 Portion Of Pivotal Trial For MRNA RSV Vaccine Candidate
VCRRX
-0.15%
Moderna (MRNA) reports Q4 earnings before market open on Feb. 24. Can it keep posting healthy profits and revenue on demand for its COVID-19 vaccine?
No comments:
Post a Comment